BJL
CTXR icon

Brighton Jones LLC’s Citius Pharmaceuticals CTXR Stock Holding History

Brighton Jones LLC’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-400
Closed -$18K – 491
2022
Q1 		$18K Hold
400
– – ﹤0.01% 512
2021
Q4 		$15K Sell
400
-800
-67% -$36.3K ﹤0.01% 528
2021
Q3 		$61K Hold
1,200
– – ﹤0.01% 478
2021
Q2 		$104K Buy
1,200
+800
+200% +$48.1K 0.01% 465
2021
Q1 		$18K Buy
+400
New +$15.9K ﹤0.01% 429

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brighton Jones LLC's CTXR Position: Q2 2022 in Review

Brighton Jones LLC sold out of Citius Pharmaceuticals (CTXR) in Q2 2022, closing a stake of 400 shares — an estimated $18K sold.

Brighton Jones LLC first reported a position in CTXR in Q1 2021 and held it in 5 quarters. The position peaked at $104K in Q2 2021. 60 funds tracked by Wall St. Rank hold CTXR as of Q2 2022.

  • Brighton Jones LLC reported no remaining Citius Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Brighton Jones LLC sold 400 Citius Pharmaceuticals shares in Q2 2022, an estimated $18K.
  • Brighton Jones LLC first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Brighton Jones LLC's Citius Pharmaceuticals position peaked at $104K in Q2 2021.
  • 60 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2022.

Based on Brighton Jones LLC's 13F filing for Q2 2022, filed 4 Aug 2022.